PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

Rhea-AI Summary

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) has announced a detailed analysis of the integration site of the cytochrome P450 2B1 gene in its pancreatic cancer product candidate, CypCaps™. Previous studies indicated the gene was located on human chromosome 9. The new findings confirm the structure of the transgene sequence and demonstrate genetic stability in cell growth. PharmaCyte aims to develop cellular therapies for cancer and diabetes using its Cell-in-a-Box® technology, which has been effective in previous clinical trials.

Positive

• Confirmation of genetic stability of cytochrome P450 2B1 gene during cell growth.
• Further validation of the transgene sequence structure enhances credibility of CypCaps™.
• Progress in research increases potential for future clinical applications.

Negative

• None.

LAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box^®, today announced the results of an additional, more finely detailed, analysis of the integration site of the cytochrome P450 2B1 gene from the augmented HEK293 cell clone that is used in PharmaCyte’s pancreatic cancer product candidate known as CypCaps™.

Previous studies that PharmaCyte conducted showed that the cytochrome P450 2B1 gene in the augmented HEK293 cell clone was located on human chromosome 9. As PharmaCyte announced on December 8, 2021, the flanking sequence around the site of integration was sequenced in its entirety. In this new study, PharmaCyte has been able to confirm the previously elucidated structure of the integrated transgene sequence using more data points.

These studies also set the stage for a next step analysis to determine the genetic stability of the cytochrome P450 2B1 gene at the DNA level after multiple rounds of cell growth. This new study was completed by comparing the original Research Cell Bank cells with cells from the Master Cell Bank, and the analysis confirmed that the cytochrome P450 2B1 and the surrounding sequence has remained stable with no changes detected at the DNA level.

To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced, inoperable pancreatic cancer, we encourage you to watch PharmaCyte’s documentary video complete with medical animations at: https://www.PharmaCyte.com/Cancer

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box^®.” This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and we believe results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. The encapsulation of the cell line will be done using the Cell-in-a-Box technology. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance, and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to raise the necessary capital to fund our operations and to find partners to supplement our capabilities and resources, our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward- looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220222005345/en/

Investor Relations:

Dr. Gerald W. Crabtree

PharmaCyte Biotech, Inc.

Telephone: 917.595.2856

Email: InvestorRelations@PharmaCyte.com

Source: PharmaCyte Biotech, Inc.

FAQ

What are the recent developments announced by PharmaCyte Biotech regarding CypCaps™?

PharmaCyte announced a detailed analysis confirming the genetic stability of the cytochrome P450 2B1 gene used in its pancreatic cancer treatment CypCaps™.

How does PharmaCyte's technology work in treating pancreatic cancer?

PharmaCyte's therapy involves encapsulating genetically engineered cells that activate an inactive chemotherapy drug at the tumor site, potentially leading to effective treatment with fewer side effects.

What is the significance of the integration site analysis for PharmaCyte's CypCaps™?

The analysis confirms the structural integrity of the transgene sequence and supports the genetic stability of the therapy, which is critical for its efficacy.

What is the stock symbol for PharmaCyte Biotech?

The stock symbol for PharmaCyte Biotech is PMCB.

What is the future outlook for PharmaCyte Biotech following this announcement?

With positive validation of its research, PharmaCyte may enhance its position in the market for cancer treatments, though it must address FDA requirements for clinical trials.